- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04718376
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
March 5, 2024 updated by: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer
This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer.
At least 30 subjects will be recruited in this study.
The subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2 by an intravenous infusion (IV), every 21 days (q3w, 1 cycle).
All patients will receive the treatment until disease progression, intolerable toxic reaction, death, or withdrawal by investigator or patient decision (a maximum of 8 cycles).
Delays in drug administration is allowed from the cycle 2, however, the delays should be no more than 3 weeks.
Dose adjustments after the cycle 2 is permitted, and the minimum dose is 12mg/m2.
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400030
- Chongqing University Cancer Hospital
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Fujian cancer hospital
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- Guangxi Medical University Cancer Hospital
-
-
Guizhou
-
Guiyang, Guizhou, China, 550000
- Guizhou Cancer Hospital
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Harbin Medical University Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects fully understand and voluntarily participate in this study and sign informed consent;
- Age ≥18, female;
- Histologically confirmed diagnosis of epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma (excluding low grade serous carcinoma and mucous carcinoma);
- Fail to respond to or progressed on the standard platinum-based therapy ;
- At least one measurable lesion according to RECIST v1.1;
- ECOG performance status of 0 to 2;
- Life expectancy ≥ 12 weeks;
- AEs from the previous treatment have resolved to ≤ Grade 1 based on CTCAE (except for the toxicity without safety risk judged by the investigator, such as hair loss, hyperpigmentation);
- Adequate organ function;
- Subjects of childbearing potential must agree to use effective contraceptive measures. Female subjects must have a negative pregnancy test before enrolment;
- Fully comply with the protocol.
Exclusion Criteria:
- History of allergy to mitoxantrone hydrochloride or any excipients of the study drug;
- Untreated or symptomatic central nervous system (CNS) metastases;
- Pericardial effusion with clinical symptoms
- History of allotransplantation;
- Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or other active viral infection;
- Serious infection or interstitial pneumonia within 1 week prior to the first dose administration;
- Use of other anticancer treatment within 4 weeks prior to the first dose administration;
- Enrolled in any other clinical trials within 4 weeks prior to the first dose administration;
- Major surgery within 3 months prior to the first dose administration, or have a surgical schedule during the study period;
- Thrombosis or thromboembolism within 6 months prior to screening;
- History of, or known additional malignant tumor within 3 years, except for tumors have been cured and have not recurred, and carcinoma in situ;
- Impaired cardiac function or serious cardiac disease;
- Previous treatment with adriamycin or other anthracyclines, and the total cumulative dose of prior adriamycin or equivalent is >350 mg/m2.
- Pregnant or lactating female;
- Serious and/or uncontrolled systemic diseases;
- Not suitable for this study as decided by the investigator due to other reasons.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mitoxantrone Hydrochloride Liposome Injection
Subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome every 21 days (a cycle) for a maximum of 8 cycles.
|
All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse events (AEs)
Time Frame: from the initiation of the first dose to 28 days after the last dose,assessed up to 36 months
|
The incidence and severity of AEs, abnormalities in physical exams, vital sign assessments, clinical laboratory assessments, ultrasonic cardiograms (UCGs) and electrocardiographs (ECGs).
|
from the initiation of the first dose to 28 days after the last dose,assessed up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall response rate (ORR)
Time Frame: From the enrollment to the final documentation of response of the last subject (assessed up to 36 months)
|
To investigate the preliminary antitumor efficacy
|
From the enrollment to the final documentation of response of the last subject (assessed up to 36 months)
|
duration of response (DoR)
Time Frame: From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months
|
To investigate the preliminary antitumor efficacy
|
From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months
|
progression-free survival (PFS)
Time Frame: From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months
|
To investigate the preliminary antitumor efficacy
|
From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months
|
duration of complete response (DCR)
Time Frame: From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months
|
To investigate the preliminary antitumor efficacy
|
From the enrollment to death, lost to follow-up, withdrawal, or study end, whichever occurred first, assessed up to 36 months
|
overall survival (OS)
Time Frame: From the enrollment to the death of last subject or the end of the clinical trial (assessed up to 36 months)
|
To investigate the preliminary antitumor efficacy
|
From the enrollment to the death of last subject or the end of the clinical trial (assessed up to 36 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Qi Zhou, Master, Chongqing University Cancer Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 12, 2021
Primary Completion (Actual)
May 22, 2023
Study Completion (Actual)
May 22, 2023
Study Registration Dates
First Submitted
December 14, 2020
First Submitted That Met QC Criteria
January 20, 2021
First Posted (Actual)
January 22, 2021
Study Record Updates
Last Update Posted (Actual)
March 7, 2024
Last Update Submitted That Met QC Criteria
March 5, 2024
Last Verified
May 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Mitoxantrone
Other Study ID Numbers
- HE071-CSP-015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Platinum-resistant Ovarian Cancer
-
Aduro Biotech, Inc.Incyte CorporationTerminatedPlatinum-resistant Ovarian Cancer | Platinum-resistant Fallopian Cancer | Platinum-resistant Peritoneal CancerUnited States, Canada
-
Seoul National University HospitalPharos iBio Co., Ltd.RecruitingPlatinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-refractory Ovarian CarcinomaKorea, Republic of
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedPlatinum Resistant Ovarian CancerUnited States
-
Shattuck Labs, Inc.Enrolling by invitationOvarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal CarcinomaUnited States, United Kingdom, Spain, Canada
-
Xennials Therapeutics Australia Pty LtdPinotbio, Inc.TerminatedAdvanced Solid Tumor | High-grade Glioma | Platinum-Resistant Ovarian Cancer | Platinum-Resistant Urothelial CarcinomaAustralia
-
TILT Biotherapeutics Ltd.Merck Sharp & Dohme LLCRecruitingPlatinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditionsUnited States, Finland
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingPlatinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8United States
-
Nuvation Bio Inc.RecruitingPancreatic Cancer | Advanced Solid Tumor | HER2-negative Breast Cancer | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Platinum-resistant Ovarian Cancer (PROC)United States
-
Mersana TherapeuticsIQVIA Biotech; PSI CRORecruitingPlatinum Resistant Ovarian Cancer | Non Small Cell Lung Cancer MetastaticUnited States, Spain, United Kingdom, Australia, France, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, Hungary, Italy, Lithuania, New Zealand, Norway, Poland, Sweden
-
Roswell Park Cancer InstituteActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Refractory Ovarian... and other conditionsUnited States
Clinical Trials on Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Active, not recruitingAdvanced Solid TumorChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedAdvanced Gastric CarcinomaChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingPeripheral T Cell LymphomaChina
-
Hui ZengCSPC Ouyi Pharmaceutical Co., Ltd.RecruitingRelapsed or Refractory Acute Myeloid LeukemiaChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingA Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic CancerAdvanced Pancreatic Cancer
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedRecurrent/Refractory LymphomaChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownRelapsed or Refractory Peripheral T-cell and NK/T-cell LymphomaChina
-
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....Not yet recruitingNeuromyelitis Optica Spectrum Disorder
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedUnresectable or Metastatic Bone and Soft Tissue SarcomaChina